@article{95d6db8f120943518469fb08d0a0ab05,
title = "A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma",
abstract = "INO-1001 is a PARP-1 inhibitor that interrupts the repair process of N-methylpurines generated by temozolomide. We evaluated the pharmacokinetics of INO-1001 and determined its safety when used with temozolomide at 200 mg/m2/day x 5 days every 4 weeks. We enrolled 12 adult patients, in cohorts of 3-6 patients, into the study. INO-1001 at doses of 100, 200 and 400 mg was given intravenous for 1 hr q 12 hr for 10 doses. INO-1001 had a moderate clearance, volume of distribution and a relatively short terminal half-life. Myelosuppression and elevation of liver transaminases were dose-limiting toxicities (DLTs) of INO-1001 at 400 mg.",
keywords = "INO-1001, Melanoma, PARP inhibitor, Pharmacokinetics, Temozolomide",
author = "Bedikian, {Agop Y.} and Papadopoulos, {Nicholas E.} and Kim, {Kevin B.} and Hwu, {Wen Jen} and Jade Homsi and Glass, {Michelle R.} and Suzanne Cain and Patrick Rudewicz and Laurent Vernillet and Patrick Hwu",
note = "Funding Information: Keywords: Temozolomide, INO-1001, PARP inhibitor, Pharmacokinetics, Melanoma This study was supported by Inotek Pharmaceuticals Corporation and Genentech, Inc. The authors acknowledge Sravanthi Cheeti for her assistance in data acquisition, pharmacokinetic, and biostatistical calculations. This study has neither been published nor has been submitted simultaneously for publication elsewhere. Correspondence to: Dr. Agop Y. Bedikian Department of Melanoma Medical Oncology, Unit 430 The University of Texas M.D. Anderson Cancer Center 1515 Holcombe Boulevard Houston, TX 77030 USA email: abedikia@mdanderson.org",
year = "2009",
month = aug,
doi = "10.1080/07357900802709159",
language = "English (US)",
volume = "27",
pages = "756--763",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "7",
}